Research

Hormonal

GLP-1 agonists (semaglutide 2.4 mg SC weekly and tirzepatide 5-15 mg SC weekly) produce profound weight loss (15-21% body weight reduction) in overweight/obese adults, significantly outperforming placebo and existing pharmacologic strategies like metformin.

If you are struggling with significant weight gain, particularly from psychiatric medications, GLP-1 agonists like semaglutide or tirzepatide offer the most effective pharmacological solution currently available, capable of producing 15-20% body weight loss. These require weekly injections and lifestyle changes, and while they cause transient gastrointestinal side effects, their efficacy far exceeds older options like metformin. Consult your provider to see if you qualify based on BMI and medical history.

GoodSupportsHIGH confidence
The use of a relatively new class of incretin mimetics called glucagon-like peptide 1 (GLP-1) agonists... has been associated with profound and often dramatic weight loss and improvement of glycemic parameters in patients with obesity and glycemic dysregulation.
Joseph F. Goldberg · Current Psychiatry · 2023

Why this rating

Based on multiple randomized controlled trials (RCTs) and meta-analyses cited (Wilding et al., Jastreboff et al.), though the paper itself is a review.

Source

GLP -1 agonists for weight loss: What you need to know

Joseph F. Goldberg · Current Psychiatry · 2023

DOI 10.12788/cp.0318

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →